$GLUE
Monte Rosa Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024447 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.65M $7.020M $4.753M
YoY Change 159.65% 47.7% 420.02%
% of Gross Profit
Research & Development $24.87M $21.34M $15.12M
YoY Change 37.16% 41.2% 176.22%
% of Gross Profit
Depreciation & Amortization $1.070M $1.100M $582.0K
YoY Change 32.26% 89.0% 139.51%
% of Gross Profit
Operating Expenses $32.49M $28.36M $19.87M
YoY Change 38.92% 42.75% 211.12%
Operating Profit -$28.36M -$19.87M
YoY Change 42.75% 211.12%
Interest Expense $1.707M $997.0K $13.00K
YoY Change -3320.75% 7569.23% 550.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $1.044M $31.00K
YoY Change 3267.74% -118.02%
Pretax Income -$30.78M -$27.32M -$19.84M
YoY Change 31.32% 37.71% 202.49%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$30.78M -$27.32M -$19.84M
YoY Change 31.32% 37.71% 202.49%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.63 -$584.6K -$431.4K
COMMON SHARES
Basic Shares Outstanding 48.40M 46.71M 46.38M
Diluted Shares Outstanding 46.73M 45.99M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $262.8M $272.1M $367.0M
YoY Change -24.05% -25.85%
Cash & Equivalents $54.91M $112.4M $367.0M
Short-Term Investments $207.9M $159.8M
Other Short-Term Assets $5.404M $5.529M $3.485M
YoY Change 108.25% 58.65%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $275.9M $295.2M $370.5M
YoY Change -20.87% -20.32%
LONG-TERM ASSETS
Property, Plant & Equipment $27.08M $19.38M $11.80M
YoY Change 119.68% 64.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $278.0K $148.0K $1.729M
YoY Change -91.44%
Total Long-Term Assets $66.50M $62.37M $13.53M
YoY Change 276.51% 360.96%
TOTAL ASSETS
Total Short-Term Assets $275.9M $295.2M $370.5M
Total Long-Term Assets $66.50M $62.37M $13.53M
Total Assets $342.4M $357.6M $384.0M
YoY Change -6.54% -6.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.862M $9.753M $3.530M
YoY Change 19.88% 176.29%
Accrued Expenses $17.71M $12.04M $9.213M
YoY Change 75.66% 30.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.57M $21.79M $12.74M
YoY Change 53.68% 71.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $45.41M $44.72M $2.001M
YoY Change 1986.72% 2134.93%
Total Long-Term Liabilities $45.41M $44.72M $2.001M
YoY Change 1986.72% 2134.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.57M $21.79M $12.74M
Total Long-Term Liabilities $45.41M $44.72M $2.001M
Total Liabilities $70.98M $66.51M $14.74M
YoY Change 277.25% 351.11%
SHAREHOLDERS EQUITY
Retained Earnings -$230.5M -$199.8M -$98.60M
YoY Change 88.88% 102.64%
Common Stock $503.7M $493.4M $469.9M
YoY Change 6.81% 5.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $271.4M $291.1M $369.3M
YoY Change
Total Liabilities & Shareholders Equity $342.4M $357.6M $384.0M
YoY Change -6.54% -6.89%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$30.78M -$27.32M -$19.84M
YoY Change 31.32% 37.71% 202.49%
Depreciation, Depletion And Amortization $1.070M $1.100M $582.0K
YoY Change 32.26% 89.0% 139.51%
Cash From Operating Activities -$23.96M -$20.60M -$17.79M
YoY Change 69.07% 15.77% 60.26%
INVESTING ACTIVITIES
Capital Expenditures $7.271M -$1.400M -$1.755M
YoY Change -337.69% -20.23% -19.86%
Acquisitions
YoY Change
Other Investing Activities -$46.67M $30.89M $67.00K
YoY Change -389000.0% 46002.99%
Cash From Investing Activities -$53.94M $29.49M -$1.688M
YoY Change 1670.23% -1846.98% -22.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.43M -217.0K 29.46M
YoY Change -15236.3% -100.74% -50.96%
NET CHANGE
Cash From Operating Activities -23.96M -20.60M -17.79M
Cash From Investing Activities -53.94M 29.49M -1.688M
Cash From Financing Activities 20.43M -217.0K 29.46M
Net Change In Cash -57.47M 8.672M 9.974M
YoY Change 231.14% -13.05% -78.68%
FREE CASH FLOW
Cash From Operating Activities -$23.96M -$20.60M -$17.79M
Capital Expenditures $7.271M -$1.400M -$1.755M
Free Cash Flow -$31.23M -$19.20M -$16.04M
YoY Change 181.04% 19.71% 79.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
128000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40522
dei Entity Registrant Name
EntityRegistrantName
Monte Rosa Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3766197
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
dei Entity Central Index Key
EntityCentralIndexKey
0001826457
dei Amendment Flag
AmendmentFlag
false
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-03-31
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address Address Line1
EntityAddressAddressLine1
645 Summer Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
949-2643
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
GLUE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48399056
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112394000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
346071000
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
159755000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q3 glue Proceeds Receivable From Common Stock Sale
ProceedsReceivableFromCommonStockSale
13507000
CY2021Q4 glue Proceeds Receivable From Common Stock Sale
ProceedsReceivableFromCommonStockSale
0
CY2022Q3 us-gaap Other Receivables
OtherReceivables
4050000
CY2021Q4 us-gaap Other Receivables
OtherReceivables
0
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4569000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2595000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
960000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2022Q3 us-gaap Assets Current
AssetsCurrent
295235000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
348666000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19384000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12325000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
38534000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4302000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5338000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
148000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2022Q3 us-gaap Assets
Assets
357603000
CY2021Q4 us-gaap Assets
Assets
366329000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9753000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6558000
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8972000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10080000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3065000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
21790000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16638000
CY2022Q3 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2128000
CY2021Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2176000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
42593000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q3 us-gaap Liabilities
Liabilities
66511000
CY2021Q4 us-gaap Liabilities
Liabilities
18814000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48528247
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48372781
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46794295
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46535966
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
493443000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
471566000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2602000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2021000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199754000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122035000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
291092000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
347515000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
357603000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
366329000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21342000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15115000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60193000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39025000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7020000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4753000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19702000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10470000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
28362000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
19868000
us-gaap Operating Expenses
OperatingExpenses
79895000
us-gaap Operating Expenses
OperatingExpenses
49495000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28362000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19868000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79895000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49495000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
997000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
13000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1774000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
33000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
63000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
18000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
293000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-96000
CY2022Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-16000
CY2021Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
109000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2022Q3 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
0
CY2021Q3 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
0
glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
0
glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
-960000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1044000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
31000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2176000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1023000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-27318000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-19837000
us-gaap Net Income Loss
NetIncomeLoss
-77719000
us-gaap Net Income Loss
NetIncomeLoss
-50518000
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.58
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.58
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.43
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.43
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.67
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.67
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.85
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.85
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46732353
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46732353
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45987866
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45987866
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46666000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46666000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17751410
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17751410
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-27318000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-19837000
us-gaap Net Income Loss
NetIncomeLoss
-77719000
us-gaap Net Income Loss
NetIncomeLoss
-50518000
CY2022Q3 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
32000
CY2021Q3 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
-535000
glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
99000
glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
-894000
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
176000
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
680000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27462000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20372000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78300000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51412000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
347515000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153000
CY2022Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
34000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2251000
CY2022Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
146000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23932000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
325875000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
96000
CY2022Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
33000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2873000
CY2022Q2 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
358000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26469000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
302050000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
79000
CY2022Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
32000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3214000
CY2022Q3 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
176000
CY2022Q3 glue Issuance Of Common Stock Net Of Issuance Costs
IssuanceOfCommonStockNetOfIssuanceCosts
13211000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-27318000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
291092000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-48728000
CY2021Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
136000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
252000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12276000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-60616000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2021Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
231172000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
203875000
CY2021Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-495000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1019000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-18405000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
356678000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30926000
CY2021Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-535000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2073000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-19837000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
369305000
us-gaap Profit Loss
ProfitLoss
-77719000
us-gaap Profit Loss
ProfitLoss
-50518000
us-gaap Share Based Compensation
ShareBasedCompensation
8338000
us-gaap Share Based Compensation
ShareBasedCompensation
3344000
us-gaap Depreciation
Depreciation
2675000
us-gaap Depreciation
Depreciation
1323000
glue Noncash Lease Expense
NoncashLeaseExpense
3202000
glue Noncash Lease Expense
NoncashLeaseExpense
0
glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
-685000
glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
0
glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
0
glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
-960000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
109000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-13000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
177000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2122000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1593000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-899000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5446000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1041000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6726000
us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
-50000
us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
0
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-18000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68505000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45191000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5640000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6673000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
109000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
67000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
290049000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
130300000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-165280000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6606000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
143000000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
231000
glue Proceeds From Initial Public Offering Net Of Underwriting Discount
ProceedsFromInitialPublicOfferingNetOfUnderwritingDiscount
17900000
glue Proceeds From Initial Public Offering Net Of Underwriting Discount
ProceedsFromInitialPublicOfferingNetOfUnderwritingDiscount
17900000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
237750000
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
0
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
2950000
glue Payment Of Common Stock Issuance Cost
PaymentOfCommonStockIssuanceCost
296000
glue Payment Of Common Stock Issuance Cost
PaymentOfCommonStockIssuanceCost
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
328000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
377697000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-233753000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
325900000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
351409000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42863000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117656000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
368763000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112394000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
367034000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
5262000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
1729000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117656000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
368763000
glue Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
0
glue Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
231172000
glue Settlement Of Preferred Stock Tranche Obligation
SettlementOfPreferredStockTrancheObligation
0
glue Settlement Of Preferred Stock Tranche Obligation
SettlementOfPreferredStockTrancheObligation
20640000
glue Common Stock Issuance Costs In Accounts Payable
CommonStockIssuanceCostsInAccountsPayable
31000
glue Common Stock Issuance Costs In Accounts Payable
CommonStockIssuanceCostsInAccountsPayable
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13507000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
glue Reduction Of Right Of Use Assets For Lease Incentives Receivable
ReductionOfRightOfUseAssetsForLeaseIncentivesReceivable
3872000
glue Reduction Of Right Of Use Assets For Lease Incentives Receivable
ReductionOfRightOfUseAssetsForLeaseIncentivesReceivable
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4750000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1909000
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-3.5305
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199800000
us-gaap Net Income Loss
NetIncomeLoss
-77700000
us-gaap Net Income Loss
NetIncomeLoss
-50500000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
272100000
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
13000000
CY2022Q3 glue Receivable In Tenant Improvements
ReceivableInTenantImprovements
3900000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2033754
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.04
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y4M24D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6378000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7300000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
7400000
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
264651000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
160435000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
686000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
159755000
glue Number Of Marketable Securities Held
NumberOfMarketableSecuritiesHeld
27
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
118100000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24564000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15028000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5180000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2703000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19384000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12325000
CY2022Q3 us-gaap Depreciation
Depreciation
1100000
CY2021Q3 us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
2700000
us-gaap Depreciation
Depreciation
1300000
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
us-gaap Operating Lease Cost
OperatingLeaseCost
4857000
us-gaap Variable Lease Cost
VariableLeaseCost
1128000
us-gaap Lease Cost
LeaseCost
5985000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Company’s board of directors approved a one-for-3.5305 reverse stock split of its issued and outstanding common stock and stock options and a proportional adjustment to the existing conversion ratios for the Company’s preferred stock effective as of June 17, 2021
CY2021Q2 glue Stockholders Equity Note Reverse Stock Split Conversion Ratio
StockholdersEquityNoteReverseStockSplitConversionRatio
1
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48528247
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y10M24D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
48488000
glue Cash Paid For Amount Included In Measurement Of Lease Liabilities
CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities
1181000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14897000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
3160000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
8353000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
8583000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
8820000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
7298000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
44360000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
80574000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48372781
CY2022Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
-0
us-gaap Payments Of Dividends
PaymentsOfDividends
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7453509
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5821842
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5563513
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.92
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
70045000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1954775
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.76
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
95726
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
215519
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.41
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7207043
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.16
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
1200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
200000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46666000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17751410
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17751410
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8338000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3344000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-27318000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-19837000
us-gaap Net Income Loss
NetIncomeLoss
-77719000
us-gaap Net Income Loss
NetIncomeLoss
-50518000
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.58
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.58
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.43
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.43
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.67
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.67
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.85
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.85
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46732353
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46732353
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45987866
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45987866
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46666000
CY2022Q3 us-gaap Defined Benefit Plan Administration Expenses
DefinedBenefitPlanAdministrationExpenses
200000
CY2021Q3 us-gaap Defined Benefit Plan Administration Expenses
DefinedBenefitPlanAdministrationExpenses
100000
us-gaap Defined Benefit Plan Administration Expenses
DefinedBenefitPlanAdministrationExpenses
600000
us-gaap Defined Benefit Plan Administration Expenses
DefinedBenefitPlanAdministrationExpenses
300000
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2022Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2021Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000

Files In Submission

Name View Source Status
0000950170-22-024447-index-headers.html Edgar Link pending
0000950170-22-024447-index.html Edgar Link pending
0000950170-22-024447.txt Edgar Link pending
0000950170-22-024447-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
glue-20220930.htm Edgar Link pending
glue-20220930.xsd Edgar Link pending
glue-ex31_1.htm Edgar Link pending
glue-ex31_2.htm Edgar Link pending
glue-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
glue-20220930_cal.xml Edgar Link unprocessable
glue-20220930_pre.xml Edgar Link unprocessable
glue-20220930_lab.xml Edgar Link unprocessable
glue-20220930_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
glue-20220930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable